MET and non-small cell lung carcinoma: The MET exon 14 skipping transcript is an emerging biomarker in metastatic non-small cell lung cancer [43,44,45,46,47] and other solid tumour types [48] that predicts sensitivity to capmatinib, crizotinib, and tepotinib.